As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama sheds light on the pharmaceuticals industry behind them ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Researchers, including experts from the University of Missouri School of Medicine, explored the use of senolytics—drugs ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...